This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The costing was undertaken retrospectively on the same patient sample that provided the effectiveness evidence.
Study sample
The authors estimated that "a convenience sample of 50 treatment courses/phase would have been adequate" in both groups. However, no power calculations were performed. The sample was selected using random number-generating software. The control group was defined by the 6-month period before the intervention (phase I), while the intervention group was defined by the 6-month period after the intervention (phase II). Before the intervention, the patients received 400-mg i.v. ciprofloxacin every 12 hours. During phase I (control group), 46 treatment courses were begun in 42 febrile neutropenic patients. In phase II (intervention group), 42 treatment courses were begun in 36 patients.
Study design
This was a single-centre, non-randomised study that examined patients during their hospital stay. Investigators who were blinded to the patient's treatment group assessed patient outcomes. The duration of follow-up was until discharge.
Analysis of effectiveness
It appears that the analysis was conducted on the basis of treatment completers only. The primary health outcomes used were cure or improvement, or failure. Cure or improvement was defined as afebrile with complete or incomplete resolution of other signs and symptoms of infection, and no other evidence of infection at the end of ciprofloxacin therapy. Failure was defined as no significant resolution of the signs of infection or intolerance to ciprofloxacin, resulting in its discontinuation.
Microbiological outcomes were also assessed on the basis of eradication, persistence, colonisation, or superinfection. If cultures at the end of therapy were unavailable, eradication was assumed if clinical cure or improvement was obtained.
The frequency of adverse drug reactions (ADRs) was also measured. The likelihood of an association of an ADR with ciprofloxacin was determined on the basis of the following criteria: known ADR; temporal relationship, ADR disappeared with dosage reduction or discontinuation of ciprofloxacin; symptoms could not be explained by any other known condition or predisposition of the patient; and symptoms reappeared on rechallenge with ciprofloxacin.
An ADR was definite (all five criteria were satisfied), probable (the first four criteria were satisfied), possible (the first three criteria were satisfied), or unlikely-unevaluable.
The two patient groups were shown to be comparable in terms of demographics but there was a difference in health profiles. There were more BMT recipients in the control group, (p=0.02). The duration of therapy was similar between the groups.
Effectiveness results
There was no statistically significant difference in clinical outcomes between the two treatment groups:
83% of treatment courses in the control group and 81% of the treatment courses in the stepdown group resulted in cure or improvement, (p=0.81); the eradication rates of bacterial infection were similar between the two treatment courses, (chi-squared 1.0);
